Shen Wencui, Huang Bingqing, Yang Jin
Tianjin Eye Hospital & Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science, Nankai University, Tianjin, China.
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
J Ophthalmol. 2019 Dec 10;2019:9798272. doi: 10.1155/2019/9798272. eCollection 2019.
Glaucoma is the second leading cause of blindness globally. Reducing intraocular pressure (IOP) has been acknowledged to be the main therapy for glaucoma. Prostaglandin analogues (PGAs) have become the first-line therapy for patients with glaucoma due to their powerful efficacy for lowering (IOP). However, usage of PGAs can also cause several notable side effects, including the changes in ocular surface. The relationship between PGAs and ocular surface changes is complicated and still remains unclear. In the present review, we summarize the recent studies of the effects of PGAs on ocular changes as well as the possible mechanisms that might provide new considerations during clinical medication.
青光眼是全球第二大致盲原因。降低眼压（IOP）已被公认为是青光眼的主要治疗方法。前列腺素类似物（PGAs）因其强大的降眼压功效，已成为青光眼患者的一线治疗药物。然而，使用PGAs也会引起一些显著的副作用，包括眼表变化。PGAs与眼表变化之间的关系复杂，仍不清楚。在本综述中，我们总结了PGAs对眼部变化影响的最新研究以及可能的机制，这可能为临床用药提供新的思考。
